NKTR: Nektar Price to Sales

Corporate company logo of Nektar Corp (NKTR)

The price/sales multiple of Nektar Therapeutics (NKTR) reflects the consequences of aggressive headcount reductions and a strategic pivot toward treating autoimmune pathologies. This metric stands at 24.40, necessitating a valuation assessment amid the implementation of AI screening to accelerate drug development. However, a high burn rate and the risks of clinical trial failures threaten the stability of quotes within the current sideways range.

NKTR (Nektar) P/S Multiple history from 07/04/2022 to 11/16/2026

Nektar (NKTR) - metric breakdowns and financial figures

General company analysis:NKTR Nektar Therapeutics Inc
Signature product of Nektar Therapeutics Inc

Waning confidence in the defensive patents of Nektar Therapeutics (NKTR) following failed trials is forcing the market to re-evaluate the value of its future revenues. Analyzing the price-to-sales chart, an investor can see a capitalization ratio of one dollar of sales, which allows for the determination of the asset's premium and helps avoid freezing capital by purchasing shares at the peak of the valuation range.

Competitors of Nektar Therapeutics

argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols Biemat) - P/S Multiple|P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Revenue Ratio Celldex Therapeutics (CLDX)|Price-to-Revenue Coefficient auriniapharma.com|Price-to-Revenue Ratio BioCryst Pharmaceuticals BCRX|Market Capitalization-to-Revenue Ratio VERA|Dianthus Pharma - P/S Multiple|PHVS - P/S Multiple|ABCL: P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Intrexon|PHAR - Price-to-Revenue Multiple|P/S Multiple UPB|ZBIO - Price to Sales|P/S Multiple IMNM (immunome.com)|Gossamer Bio, Inc. - Price-to-Revenue Ratio|KalVista Pharmaceuticals, Inc. - P/S Multiple|SEPN (Septerna) - Market Cap to Revenue Ratio|Pieris Corp (PVLA) - Price-to-Revenue Ratio|SVRA - Price-to-Revenue Coefficient|RIGL (rigel.com) - P/S Multiple|Market Cap to Revenue Ratio ANAB (AnaptysBio, Inc.)|P/S Multiple ATXS|enGene Holdings Inc (ENGN) - Price-to-Revenue Multiple|P/S Multiple RAPT (RAPT Therapeutics Inc.)|JBIO (Aerovate) - Price-to-Sales Ratio|ACRS: Market Cap to Revenue|KYTX - P/S Multiple|TLSA: P/S Multiple|Market Cap to Revenue Cabaletta Bio, Inc|Price-to-Revenue Ratio Ventyx Biosciences, Inc|THTX: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue AVTX (Avalo Therapeutics, Inc)|Market Cap to Revenue Eledon Pharmaceuticals ELDN|Price-to-Revenue Ratio Agenus, Inc. AGEN|P/S Multiple Climb Bio Inc. CLYM|ZURA - Price-to-Revenue Ratio|Price-to-Sales Ratio ATYR|ADAG (Adagene Inc.) - Market Cap to Revenue|ImageneBio Inc (IMA) - P/S Multiple|Price-to-Revenue Ratio Shattuck Therapeutics|Market Cap to Revenue equilliumbio.com (EQ)|P/S Multiple CNTB|Price-to-Revenue Coefficient Immunic Therapeutics|P/S Multiple ATRA (Atara Biotherapeutics, Inc.)|IFRX - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio X4 Pharmaceuticals, Inc. (XFOR)|ACET (adicetbio.com) - Market Cap to Revenue Ratio|CELU: P/S Multiple|INMB - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Barinthus Biotherapeutics plc|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|AKTX (Akari Therapeutics Plc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd)|q32bio.com - Price-to-Revenue Ratio|GOVX: Market Cap to Revenue|edesabiotech.com (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|CARM - Price-to-Revenue Coefficient|Market Cap to Revenue XTLB|Market Cap to Revenue boltbio.com (BOLT)|Price-to-Revenue Ratio HCW Biologics Inc (HCWB)|P/S Multiple Aptevo Therapeutics, Inc. (APVO)|Price-to-Revenue Ratio aimimmuno.com AIM|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio Corporation - P/S Multiple|XORTX Corp (XRTX) - Market Cap to Revenue|HIND (Vyome Holdings Inc.) - Market Cap to Revenue|revbiosciences.com (REVB) - P/S Multiple|INDP (Indaptus Corp) - P/S Multiple|Market Cap to Revenue Scinai Immunotherapeutics Ltd (SCNI)|Price-to-Revenue Ratio CalciMedica Inc (CALI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple